Drug Profile
ASN 004
Alternative Names: MUC-1 cancer vaccine - Ascend BiopharmaceuticalsLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Ascend Biopharmaceuticals
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Solid tumours
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Breast cancer in Australia (Parenteral)
- 24 Aug 2023 Discontinued - Preclinical for Solid tumours in Norway (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Breast-cancer in Australia (Parenteral, Injection)